In these pages, we have repeatedly published articles that call for improved preclinical resources for testing novel drug compounds and for optimizing targeted therapy. Similar to when waiting for buses, now two excellent resources of this type have come along at once. In two papers
A study in 633 patients who survived breast cancer showed that higher intake of ω-3 polyunsaturated fatty acids (PUFAs) reduces inflammation and fatigue. The participants completed a questionnaire about food frequency and dietary supplement, and provided a blood sample to assess C-reactive protein (CRP) levels
The American College of Physicians (ACP) has undertaken a comprehensive analysis of four major guidelines for the screening for colorectal cancer. Structured as several statements, the review states that all at-risk adults should receive individualized assessment. Average-risk adults aged ≥50 years should be screened using
Updated results of the European Randomized nudy of Screening for Prostate Cancer reveal that PSA screening significantly reduces mortality from prostate cancer, but does not affect all-cause mortality. A total of 182,160 men (50–74 years old) from eight European countries were randomly assigned to PSA-based
During the debate over Obamacare, Republicans have consistently promoted an alternative approach that involved allowing individuals to purchase health insurance across state lines. Interstate insurance purchasing was the second item in the health care section of the GOP's 2010 "Pledge to America," right after tort reform. It's also a part of Mitt Romney's plan to replace Obamacare. It makes intui
Can vaccines be more useful for some people than for others? Until now, most physicians have recommended immunizations for all infants and children, as well as for adults at various ages who may have missed shots. But new guidelines that take into account the strength of scientific evidence and individual health to determine whether specific vaccines
A panel of advisors to the Food and Drug Administration voted 13 to 1 that the regulator should approve a new once-a-day combo pill for HIV made by Gilead, the leading maker of HIV drugs. The medication is seen as crucial to Gilead's future and poses a threat to Merck's rival pill, Isentress, which must be taken twice a day.
